• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

DOACs Comparable to Warfarin in CVT DOACs Comparable to Warfarin in CVT
DOACs were just as effective as warfarin in preventing future thrombotic events in patients with cerebral venous thrombosis stroke, with less major bleeding, in the retrospective ACTION-CVT study.Medscape Medical News
Source: Medscape Critical Care Headlines - February 15, 2022 Category: Intensive Care Tags: Cardiology News Source Type: news

Arrive: A retrospective registry of Indian patients with venous thromboembolism
Conclusion: Acute DVT alone was responsible for the substantial burden of VTE in Indian patients. Bleeding was not the limiting factor for anticoagulant treatment in most patients.
Source: Indian Journal of Critical Care Medicine - March 8, 2016 Category: Intensive Care Authors: Dhanesh R KamerkarM Joseph JohnSanjay C DesaiLiesel C DsilvaSadhna J Joglekar Source Type: research

Management of Atrial Fibrillation
Atrial fibrillation remains the most prevalent cardiac arrhythmia, and its incidence is increasing as the population ages. Common conditions associated with an increased incidence include advanced age, hypertension, heart failure, and valvular heart disease. Patients with atrial fibrillation may complain of palpitations, fatigue, and decreased exercise tolerance or may be completely asymptomatic. Options for treating patients who experience atrial fibrillation include rate-controlling drugs such as digoxin, β-blockers, and calcium channel blockers or a rhythm-controlling strategy with agents such as sodium channel blo...
Source: Journal of Intensive Care Medicine - October 29, 2015 Category: Intensive Care Authors: Zamani, P., Verdino, R. J. Tags: Analytic Reviews Source Type: research

Perioperative management and therapy of bleeding complications.
Abstract The new oral anticoagulants directly inhibit either thrombin (Dabigatran, Pradaxa®,) or activated Factor X (rivaroxaban, Xarelto®, and apixaban, Eliquis®) and have been approved for thromboprophylaxis after hip and knee replacement surgery and stroke prevention in non-valvular atrial fibrillation. Moreover, rivaroxaban has been approved for the treatment of deep venous thrombosis, prevention of pulmonary embolism and anticoagulation after acute myocardial infarction. The direct FXa-inhibitor edoxaban (Lixiana®) expects approval for the prevention of stroke in atrial fibrillation in Germany in 2014. Th...
Source: Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS - March 1, 2014 Category: Intensive Care Authors: von Heymann C, Kaufner L, Körber M Tags: Anasthesiol Intensivmed Notfallmed Schmerzther Source Type: research

New direct oral oral anticoagulants (DOACs) - indications of DOACs.
Abstract The direct oral anticoagulants (DOACs) were developed because of the urgent therapeutic need due to the deficits of vitamin K antagonist therapy. The predominant indications in internal medicine are the acute treatment and secondary prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) as well as stroke prevention in patients with atrial fibrillation. For the acute therapy and secondary prevention of DVT/PE the DOACS were non inferior to low-molecular-weight heparin (LMWH) plus vitamin K antagonists at a significantly reduced rate of severe bleeding complications. Only Rivaroxaban is curr...
Source: Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS - March 1, 2014 Category: Intensive Care Authors: Darius H Tags: Anasthesiol Intensivmed Notfallmed Schmerzther Source Type: research